碧云天网站 微信公众号

碧云天生物技术/Beyotime Biotechnology
订货热线: 400-1683301或800-8283301
订货e-mail: order@beyotime.com
技术咨询: info@beyotime.com
网址: http://www.beyotime.com

升麻素苷(98%, HPLC)

产品编号	产品名称	包装
SM2235-10mM	升麻素苷(98%, HPLC)	10mM×0.2ml
SM2235-5mg	升麻素苷(98%, HPLC)	5mg
SM2235-25mg	升麻素苷(98%, HPLC)	25mg
SM2235-100mg	升麻素苷(98%, HPLC)	100mg

产品简介:

- **化学信息:**

中文名	升麻素苷
英文名	Prim-O-glucosylcimifugin
中文别名	升麻苷
英文别名	Cimifugin 7-glucoside
来源	防风*Saposhnikovia divaricata* (Trucz.) Schischk.
化合物类型	色原酮类(Chromones)
化学式	$C_{22}H_{28}O_{11}$
分子量	468.45
CAS号	80681-45-4
纯度	98%, HPLC
溶剂/溶解度	DMSO: ≥ 150 mg/ml (320.20 mM)
溶液配制	5mg加入1.07ml DMSO，或者每4.68mg加入1ml DMSO，配制成10mM溶液。



- **生物信息**

产品描述	Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.				
信号通路	JAK2/STAT3				
靶点	COX-2	iNOS	-	-	-
IC_{50}	-	-	-	-	-
体外研究	Prim-O-glucosylcimifugin (POG) is the highest content chromone and one of the major active constituents in Radix Saposhnikoviae (RS). Prim-O-glucosylcimifugin exerts anti-inflammatory effects in RAW 264.7 macrophages through the inhibition of iNOS and COX-2 expression by inhibiting JAK2/STAT3 signaling. The cytotoxicity of Prim-O-glucosylcimifugin is measured to LPS-activated Raw 264.7 macrophages. Raw 264.7 macrophages are treated with LPS (1 μg/ml) and increasing concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/ml) for 24 h and cell viability is evaluated by CCK-8 assay. Cell viability is not significantly affected after 24 h and exposure to 15-100 μg/ml Prim-O-glucosylcimifugin as compared with DMSO-treated cells (control). To investigate the anti-inflammatory effect of Prim-O-glucosylcimifugin, whether Prim-O-glucosylcimifugin can affect NO synthesis is examined in LPS-activated RAW 264.7 cells. Macrophages are treated with LPS (1 μg/ml) and various concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/ml) for 24 h. No concentrations are measured in the culture supernatants by Griess reaction. The concentrations of NO in the culture supernatants are markedly increased in response to LPS exposure, and Prim-O-glucosylcimifugin significantly inhibits LPS-induced NO production in a concentration-dependent manner.				
体内研究	Bronchoalveolar lavage fluid (BALF) is collected at 7 h after lipopolysaccharide (LPS) administration and the cytokine levels in BALF are measured by ELISA. The levels of TNF-α, IL-1β and IL-6 in BALF are increased dramatically compared with control group. However, pretreatment with Prime-O-glucosylcimifugin (2.5, 5 or 10 mg/kg) significantly down-regulates the levels of				

	TNF-α, IL-1β and IL-6 in a dose-dependent manner (P<0.05, P<0.01).
临床实验	N/A

参考文献：

1. Zhou J, et al. Pharmacogn Mag. 2017,13(51):378-384.
2. Chen N, et al. Int Immunopharmacol. 2013,16(2):139-47.

包装清单：

产品编号	产品名称	包装
SM2235-10mM	升麻素苷(98%, HPLC)	10mM×0.2ml
SM2235-5mg	升麻素苷(98%, HPLC)	5mg
SM2235-25mg	升麻素苷(98%, HPLC)	25mg
SM2235-100mg	升麻素苷(98%, HPLC)	100mg
-	说明书	1 份

保存条件：

-20℃避光保存，至少一年有效。固体粉末4℃避光保存，至少一个月有效。如果溶于非DMSO溶剂，建议分装后-80℃避光保存，预计6个月内有效。

注意事项：

- 本产品可能对人体有一定的毒害作用，请注意适当防护，以避免直接接触人体或吸入体内。
- 本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
- 为了您的安全和健康，请穿实验服并戴一次性手套操作。

使用说明：

1. 收到产品后请立即按照说明书推荐的条件保存。使用前可以在2,000-10,000g离心数秒，以使液体或粉末充分沉降至管底后再开盖使用。
2. 对于10mM溶液，可直接稀释使用。对于固体，请根据本产品的溶解性及实验目的选择相应溶剂配制成高浓度的储备液(母液)后使用。
3. 具体的最佳工作浓度请参考本说明书中的体外、体内研究结果或其它相关文献，或者根据实验目的，以及所培养的特定细胞和组织，通过实验进行摸索和优化。
4. 不同实验动物依据体表面积的等效剂量转换表请参考如下网页：
   https://www.beyotime.com/support/animal-dose.htm

Version 2021.05.13